IN8bio to Present at the Cowen 43rd Annual Healthcare Conference

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a company overview at the Cowen 43rd Annual Healthcare Conference on Tuesday, March 7, 2023 at 12:50 pm ET.

The Cowen presentation will be available live and as a replay on IN8bio’s website at https://bit.ly/3F1WEaQ.

About IN8bioIN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio is initiating INB-400, a company-sponsored Phase 2 clinical trial in newly diagnosed glioblastoma following IND clearance in late 2022. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types. For more information about IN8bio and its programs, please visit www.IN8bio.com.

Company Contact:IN8bio, Inc.Patrick McCall+ 1 646.600.6GDT (6438)[email protected]

Investors & Media Contact: Argot Partners[email protected]

You May Also Be Interested In

• Apeing Opens Stage 3 of $APEING Presale at $0.0004 as Project Advances Its 33-Stage Token Sale
• Sean Kirtz and Lady Hammers Earn 3rd Place at Midwest Nationals
• Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026